Xtl Biopharmaceuticals (XTLB) Receivables - Other (2009 - 2025)
Xtl Biopharmaceuticals (XTLB) posted quarterly Receivables - Other of $22000.0 for Q4 2025, down 77.55% year-on-year from $98000.0 in Q4 2024, and down 88.04% on a QoQ basis from $184000.0 in Q2 2025.
Xtl Biopharmaceuticals (XTLB) Receivables - Other (2009 - 2025) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Receivables - Other for 16 consecutive years, with $22000.0 the latest figure, recorded in Q4 2025.
- Quarterly Receivables - Other fell 77.55% year-over-year to $22000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22000.0 (down 77.55% YoY) and the FY2025 annual result came in at $22000.0, down 77.55% from the prior year.
- Receivables - Other slipped to $22000.0 in Q4 2025 per XTLB's latest filing, from $184000.0 in the prior quarter.
- Over the last five years, Receivables - Other for XTLB reached as high as $274000.0 in Q2 2021 and fell as low as $22000.0 in Q4 2025.
- A 5-year average of $115866.7 and a median of $110000.0 in 2021 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2024 — Receivables - Other surged 145.0% — and 2025, when it sank 77.55%.
- Year by year, Receivables - Other stood at $110000.0 in 2021, then fell by 22.73% to $85000.0 in 2022, then plunged by 52.94% to $40000.0 in 2023, then soared by 145.0% to $98000.0 in 2024, then plunged by 77.55% to $22000.0 in 2025.
- According to Business Quant data, Receivables - Other over the past three periods registered $22000.0, $184000.0, and $98000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn |
| 10 | Xtl Biopharmaceuticals | 2.51 Bn | 2.51 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22,000.00 |
| Dec 31, 2025 | 22,000.00 |
| Jun 30, 2025 | 184,000.00 |
| Jun 30, 2025 | 184,000.00 |
| Dec 31, 2024 | 98,000.00 |
| Dec 31, 2024 | 98,000.00 |
| Sep 30, 2024 | 127,000.00 |
| Sep 30, 2024 | 127,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Dec 31, 2023 | 40,000.00 |
| Dec 31, 2023 | 40,000.00 |
| Sep 30, 2023 | 77,000.00 |
| Sep 30, 2023 | 77,000.00 |
| Jun 30, 2023 | 118,000.00 |
| Jun 30, 2023 | 118,000.00 |
| Mar 31, 2023 | 66,000.00 |
| Mar 31, 2023 | 66,000.00 |